Structure Therapeutics (NASDAQ:GPCR) Reaches New 12-Month Low – Here’s What Happened

Structure Therapeutics Inc. (NASDAQ:GPCR) reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $15.31 and last traded at $16.95, with a volume of 1259016 shares. The stock had previously closed at $15.79.

Analyst Ratings Changes

Several research analysts have commented on GPCR shares. William Blair began coverage on shares of Structure Therapeutics in a report on Friday, February 28th. They issued an “outperform” rating for the company. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Structure Therapeutics in a research note on Thursday, December 19th. JMP Securities reissued a “market outperform” rating and set a $91.00 target price on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Finally, Stifel Nicolaus assumed coverage on Structure Therapeutics in a report on Wednesday, January 8th. They issued a “buy” rating and a $50.00 target price for the company. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Structure Therapeutics has an average rating of “Buy” and an average target price of $81.29.

Structure Therapeutics Price Performance

The business has a 50 day simple moving average of $23.03 and a 200 day simple moving average of $30.45. The stock has a market cap of $867.03 million, a PE ratio of -20.43 and a beta of -2.37.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.01. As a group, sell-side analysts forecast that Structure Therapeutics Inc. will post -0.82 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of GPCR. Spire Wealth Management bought a new stake in Structure Therapeutics in the fourth quarter worth $243,000. JPMorgan Chase & Co. boosted its stake in shares of Structure Therapeutics by 302.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 33,936 shares of the company’s stock worth $1,489,000 after acquiring an additional 25,500 shares in the last quarter. Barclays PLC boosted its stake in shares of Structure Therapeutics by 64.5% during the 3rd quarter. Barclays PLC now owns 81,138 shares of the company’s stock worth $3,562,000 after acquiring an additional 31,815 shares in the last quarter. Pier Capital LLC increased its holdings in shares of Structure Therapeutics by 32.7% during the 3rd quarter. Pier Capital LLC now owns 134,291 shares of the company’s stock valued at $5,894,000 after acquiring an additional 33,087 shares during the last quarter. Finally, Franklin Resources Inc. raised its stake in shares of Structure Therapeutics by 9.4% in the 3rd quarter. Franklin Resources Inc. now owns 706,106 shares of the company’s stock valued at $30,991,000 after acquiring an additional 60,397 shares in the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.